RECRUITING

Psychophysical Studies of Cancer Therapy Pain

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The Aim of this Study is to examine the feasibility of using quantitative sensory testing procedures, widely applied to the experimental study of sensory processing in humans both with and without various pain syndromes, to now characterize the psychophysical properties of neuropathic pain that has developed as a consequence of cancer therapy. Skin punch biopsies will be performed in patients with chemotherapy-induced pain to determine whether the impairment of nerve function is due to actual retraction or loss of innervation to the skin in areas affected by sensory disturbance.

Official Title

Psychophysical Studies of Cancer Therapy-Induced Pain: A Feasibility Study

Quick Facts

Study Start:2001-01-23
Study Completion:2025-04-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT00515060

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Since moderate pain, albeit brief, will be induced, this feasibility project will be limited to consenting adults, 18 years old or older, in which there is also a well established QST database.
  2. 2. The subjects must be able to understand the nature of the study and have signed consent.
  3. 3. The patients must either: a) have pain that has developed as a consequence of cancer therapy with either vinca alkaloids, taxanes, bortezomib, thalidomide, platinum-based compounds or ionizing irradiation. OR b) have no pain that has developed as a consequence of cancer therapy, and are just entering chemotherapy with taxanes, vinka alkaloids, bortezomib, thalidomide, or platinum-based compounds
  4. 4. (For Healthy Controls) Willing to participate and have signed an informed consent.
  1. 1. Patients who refuse to participate or who are determined incapable of completing the research.
  2. 2. (For Healthy Controls) Receiving anti-coagulants, immunosuppressed or diabetic.

Contacts and Locations

Study Contact

Patrick M. Dougherty, PhD
CONTACT
713-745-0438
pdougherty@mdanderson.org

Principal Investigator

Patrick M. Dougherty, PhD
PRINCIPAL_INVESTIGATOR
M.D. Anderson Cancer Center

Study Locations (Sites)

University of Texas MD Anderson Cancer Center
Houston, Texas, 77030
United States

Collaborators and Investigators

Sponsor: M.D. Anderson Cancer Center

  • Patrick M. Dougherty, PhD, PRINCIPAL_INVESTIGATOR, M.D. Anderson Cancer Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2001-01-23
Study Completion Date2025-04-30

Study Record Updates

Study Start Date2001-01-23
Study Completion Date2025-04-30

Terms related to this study

Keywords Provided by Researchers

  • Advanced Cancer
  • Therapy-Induced Pain
  • Pain Threshold
  • Sensory Tests
  • Stimuli
  • Pain

Additional Relevant MeSH Terms

  • Advanced Cancer
  • Pain